A Phase 1 interventional study of NNC0487-0111 and Placebo in Diabetes Mellitus, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 262nd largest by planned enrollment of the 494 interventional ones that give a count, is one of 2 that started in 2026, is one of 206 in phase 1, and was the 641st registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
642 studies; the count open now beside each. This study's row is marked.
First in 1989; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 87 across the 494 interventional studies, 1,497 across the 148 observational. Of the 636 that completed or were terminated, 163 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Diabetes Mellitus by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07535307Novo Nordisk A/SInvestigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes | 2027-11-11 |
Add it to your calendar (.ics) → With an account.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to find out how NNC0487-0111 affects, how the body uses insulin (a hormone that helps the body control blood sugar) and how well the pancreas works in people living with type 2 diabetes. There are 2 study treatments. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly.
Drug: NNC0487-0111
Participants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly.
Drug: NNC0487-0111
Participants will be randomized to receive NNC0487-0111 dose level 3 subcutaneously once weekly.
Drug: NNC0487-0111
Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly.
Drug: Placebo
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to the abdomen.
Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to the abdomen.
Change in M-value in Hyperinsulinaemic euglycaemic clamp (HEC)
Measured as milligram per minute per kilogram (mg/min/kg)
Time frame: Baseline to week 40
Change in M-value in HEC, normalised by lean body mass
Measured as mg/min/kg
Time frame: Baseline to week 40
Change in first-phase incremental Insulin Secretion Rate (ISR0-8 min) in Hyperglycaemic clamp (HGC)
Measured as picomole per minute per meter square (pmol/min/m\^2)
Time frame: Baseline to week 40
Change in second-phase ISR (ISR20-120 min) in HGC
Measured as pmol/min/m\^2
Time frame: Baseline to week 40
Change in total ISR (ISR0-120 min) in HGC
Measured as pmol/min/m\^2
Time frame: Baseline to week 40
Change in ISR at fixed glucose concentration (ISRg) in HGC
Measured as pmol/min/m\^2
Time frame: Baseline to week 40
Change in total insulin response [total area under curve (AUC0-120) min] in HGC
Measured as picomole per liter per minute (min\*pmol/L)
Time frame: Baseline to week 40
Change in clamp disposition index (cDI) calculated from HEC and HGC
Measured as picomole per liter per meter square per minute square per kilogram (pmol\*L/m\^2/min\^2/kg)
Time frame: Baseline to week 40
Change in cDI calculated from HEC and HGC, based on lean body mass
Measured as pmol\*L/m\^2/min\^2/kg
Time frame: Baseline to week 40
Change in β-cell glucose sensitivity (insulin secretion) from HGC
Measured as picomole per minute per meter square per millimoles per liter \[pmol/min/m\^2/ (mmol/L)\]
Time frame: Baseline to week 40
Change in β-cell glucose sensitivity from mixed meal tolerance test (MMTT) (slope of dose-response for insulin secretion vs. plasma glucose)
Measured as pmol/min/m\^2/ (mmol/L)
Time frame: Baseline to week 40
Change in glycated haemoglobin (HbA1c)
Measured as percentage (%) of HbA1c
Time frame: Baseline to week 40
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 19 months is above that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zenagamtide